

Massimiliano Fabbiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3038709/publications.pdf>

Version: 2024-02-01

105
papers

2,346
citations

201674

27
h-index

254184

43
g-index

109
all docs

109
docs citations

109
times ranked

4472
citing authors

#	ARTICLE	IF	CITATIONS
1	Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. <i>Neurology</i> , 2011, 76, 1403-1409.	1.1	217
2	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , 2021, 184, 1821-1835.e16.	28.9	180
3	Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. <i>HIV Medicine</i> , 2013, 14, 136-144.	2.2	77
4	Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2012, 12, 296.	2.9	73
5	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 109-117.	3.0	71
6	The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. <i>Frontiers in Immunology</i> , 2018, 9, 214.	4.8	71
7	Epidemiological and clinical study of viral respiratory tract infections in children from Italy. <i>Journal of Medical Virology</i> , 2009, 81, 750-756.	5.0	67
8	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	3.0	62
9	Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. <i>Clinical Microbiology and Infection</i> , 2012, 18, 449-458.	6.0	61
10	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. <i>PLoS ONE</i> , 2010, 5, e11505.	2.5	56
11	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. <i>Antiviral Therapy</i> , 2013, 18, 153-160.	1.0	52
12	Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. <i>Retrovirology</i> , 2010, 7, 56.	2.0	50
13	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. <i>PLoS ONE</i> , 2014, 9, e94768.	2.5	50
14	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) Tj ETQq0 0 0 rgBT /Overlock 10 T# 50 212 To	3.0	45
15	Efficacy and safety of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1843-1849.	3.0	38
16	Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. <i>Antibiotics</i> , 2020, 9, 500.	3.7	38
17	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+ /l/ Despite Effective HAART. <i>PLoS ONE</i> , 2015, 10, e0124741.	2.5	36
18	Comparison of cognitive performance in HIV or HCV mono-infected and HIV+HCV co-infected patients. <i>Infection</i> , 2013, 41, 1103-1109.	4.7	35

#	ARTICLE	IF	CITATIONS
19	Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility. <i>Antiviral Therapy</i> , 2015, 20, 441-447.	1.0	34
20	Cognitive reserve and neuropsychological functioning in older HIV-infected people. <i>Journal of NeuroVirology</i> , 2016, 22, 575-583.	2.1	33
21	The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. <i>Diagnostics</i> , 2020, 10, 619.	2.6	33
22	Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2048-2055.	2.6	30
23	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv043.	0.9	30
24	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. <i>Vaccine</i> , 2011, 29, 2836-2839.	3.8	29
25	Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. <i>BMC Public Health</i> , 2015, 15, 235.	2.9	29
26	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
27	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	3.0	28
28	Lipid-lowering effect of tenofovir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 682-683.	3.0	24
29	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. <i>Pharmacological Research</i> , 2011, 63, 249-253.	7.1	23
30	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23
31	Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table A1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2359-2361.	3.0	22
32	Initial antifungal strategy does not correlate with mortality in patients with candidemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 187-193.	2.9	22
33	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. <i>PLoS ONE</i> , 2016, 11, e0156523.	2.5	21
34	Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. <i>HIV Medicine</i> , 2010, 11, 326-333.	2.2	20
35	Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 185-187.	1.8	19
36	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). <i>Clinical Neuropsychologist</i> , 2016, 30, 1457-1468.	2.3	19

#	ARTICLE	IF	CITATIONS
37	Impact of Hepatitis B Vaccination in Children Born to HBsAg-Positive Mothers: a 20-year Retrospective Study. <i>Infection</i> , 2009, 37, 340-343.	4.7	18
38	Efficacy and durability of twoâ€‹<i>vs</i>. threeâ€‹drug integrase inhibitorâ€‹based regimens in virologically suppressed HIVâ€‹infected patients: Data from realâ€‹life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.	2.2	18
39	Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19812.	3.0	17
40	Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. <i>BMC Infectious Diseases</i> , 2014, 14, 26.	2.9	17
41	Detection of <i>HLA-B*57:01</i> by real-time PCR: implementation into routine clinical practice and additional validation data. <i>Pharmacogenomics</i> , 2014, 15, 319-327.	1.3	17
42	Liver fibrosis progression and clinical outcomes are intertwined. <i>Medicine (United States)</i> , 2016, 95, e4091.	1.0	17
43	Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing. <i>Journal of Clinical Virology</i> , 2007, 40, 43-45.	3.1	16
44	The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1299-1309.	1.1	16
45	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. <i>Journal of Infection</i> , 2012, 65, 439-446.	3.3	16
46	Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 219-224.	2.1	16
47	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infectionâ€‹Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	3.1	16
48	The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies. <i>PLoS ONE</i> , 2010, 5, e13619.	2.5	15
49	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	1.9	15
50	Unexpected viral relapses in hepatitis C virusâ€‹infected patients diagnosed with hepatocellular carcinoma during treatment with directâ€‹acting antivirals. <i>Hepatology</i> , 2017, 66, 992-994.	7.3	15
51	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127.	2.1	15
52	Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. <i>Infection</i> , 2011, 39, 563-569.	4.7	13
53	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. <i>Journal of Infection</i> , 2011, 62, 319-321.	3.3	13
54	Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. <i>Journal of the International AIDS Society</i> , 2014, 17, 19808.	3.0	13

#	ARTICLE	IF	CITATIONS
55	HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. <i>Vaccine</i> , 2013, 31, 2914-2918.	3.8	12
56	Asymmetry of the Regimen Is Correlated to Self-Reported Suboptimal Adherence: Results From AdUCSC, a Cohort Study on Adherence in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 411-412.	2.1	11
57	Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011, 30, 541-549.	2.9	11
58	Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. <i>Journal of Medical Virology</i> , 2011, 83, 2057-2065.	5.0	11
59	Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. <i>AIDS Research and Therapy</i> , 2012, 9, 18.	1.7	11
60	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. <i>BMC Psychology</i> , 2013, 1, 3.	2.1	11
61	Baseline CD4 ⁺ T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2015, 20, 433-440.	1.0	11
62	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , 2016, 73, 619-623.	3.3	11
63	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the 'cortical hypothesis' of NeuroAIDS. <i>Applied Neuropsychology Adult</i> , 2017, 24, 410-419.	1.2	11
64	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , 2019, 20, 92-98.	1.1	10
65	Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1599-1603.	3.0	10
66	Variability of Raltegravir Plasma Levels in the Clinical Setting. <i>Pharmacology</i> , 2013, 92, 43-48.	2.2	9
67	Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 258-263.	2.0	9
68	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	1.0	9
69	Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 173-179.	1.9	9
70	Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. <i>Diagnostics</i> , 2021, 11, 1154.	2.6	9
71	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. <i>Future Microbiology</i> , 2015, 10, 15-20.	2.0	8
72	Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients. <i>Journal of NeuroVirology</i> , 2019, 25, 866-873.	2.1	8

#	ARTICLE	IF	CITATIONS
73	Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab103.	0.9	8
74	Combining social and genetic networks to study HIV transmission in mixing risk groups. <i>European Physical Journal: Special Topics</i> , 2013, 222, 1377-1387.	2.6	7
75	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. <i>Journal of the International AIDS Society</i> , 2014, 17, 19817.	3.0	7
76	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1352-1355.	6.0	6
77	Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis. <i>Infection</i> , 2014, 42, 775-8.	4.7	6
78	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. <i>BMC Infectious Diseases</i> , 2016, 16, 401.	2.9	6
79	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2394-2399.	3.0	6
80	Liver fibrosis is associated with cognitive impairment in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19722.	3.0	5
81	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016, 48, 48-55.	2.8	5
82	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. <i>Journal of Immunoassay and Immunochemistry</i> , 2016, 37, 189-200.	1.1	5
83	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017, 29, 299-307.	1.5	5
84	Antimicrobial Stewardship: From Bedside to Theory. Thirteen Examples of Old and More Recent Strategies from Everyday Clinical Practice. <i>Antibiotics</i> , 2020, 9, 398.	3.7	5
85	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.	3.3	5
86	Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. <i>HIV Medicine</i> , 2022, , .	2.2	5
87	Immune response to influenza A(H1N1)v in HIV-infected patients. <i>Journal of Infection in Developing Countries</i> , 2014, 8, 101-109.	1.2	4
88	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	4.7	4
89	Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e18-e20.	2.1	3
90	Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. <i>HIV Medicine</i> , 2016, 17, 385-389.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3621-3622.	3.0	3
92	Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 569-571.	1.9	3
93	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infectected patients treated in a realâ€life setting. <i>Journal of Viral Hepatitis</i> , 2021, 28, 558-568.	2.0	3
94	Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, , 1.	2.1	3
95	Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection. <i>Diagnostics</i> , 2022, 12, 14.	2.6	3
96	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19802.	3.0	2
97	Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e45-e47.	2.1	2
98	Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. <i>Respiratory Medicine</i> , 2021, 179, 106341.	2.9	2
99	Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk. <i>Journal of the International AIDS Society</i> , 2014, 17, 19570.	3.0	1
100	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014, 68, 500-503.	3.3	1
101	Reply. <i>Hepatology</i> , 2017, 66, 2091-2092.	7.3	1
102	The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition. <i>Journal of NeuroVirology</i> , 2020, 26, 899-907.	2.1	1
103	Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1354-1356.	3.0	1
104	Reply. <i>Hepatology</i> , 2018, 67, 1182-1183.	7.3	0
105	Atazanavir-Induced Severe Episodes of Kidney Stones in an HIV-1-Infected Subject Characterized by a CYP3A Poor Metabolizer Phenotype. <i>British Journal of Pharmaceutical Research</i> , 2014, 4, 2594-2598.	0.4	0